| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | 88.55% | JMP Securities | $25 → $27 | Maintains | Market Outperform |
| 11/03/2023 | 95.53% | HC Wainwright & Co. | $27 → $28 | Maintains | Buy |
| 08/04/2023 | 88.55% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
| 08/04/2023 | 74.58% | JMP Securities | $24 → $25 | Maintains | Outperform |
| 05/03/2023 | 67.6% | JMP Securities | $25 → $24 | Maintains | Outperform |
| 05/03/2023 | 88.55% | HC Wainwright & Co. | → $27 | Reiterates | → Buy |
| 02/24/2023 | 74.58% | JMP Securities | $22 → $25 | Maintains | Market Outperform |
| 02/24/2023 | 88.55% | HC Wainwright & Co. | $28 → $27 | Maintains | Buy |
| 11/04/2022 | 46.65% | Goldman Sachs | $24 → $21 | Maintains | Buy |
| 09/27/2022 | 53.63% | JMP Securities | → $22 | Initiates Coverage On | → Market Outperform |
| 12/29/2021 | 95.53% | HC Wainwright & Co. | $23 → $28 | Maintains | Buy |
| 08/31/2021 | 60.61% | HC Wainwright & Co. | $20 → $23 | Maintains | Buy |
| 08/06/2021 | 32.68% | Goldman Sachs | → $19 | Initiates Coverage On | → Buy |
| 08/05/2021 | 39.66% | HC Wainwright & Co. | $16 → $20 | Maintains | Buy |
| 02/01/2021 | 4.75% | HC Wainwright & Co. | $14 → $15 | Maintains | Buy |
| 11/06/2020 | -2.23% | HC Wainwright & Co. | $12 → $14 | Maintains | Buy |
| 08/07/2020 | -16.2% | HC Wainwright & Co. | $14 → $12 | Maintains | Buy |
| 08/03/2020 | -2.23% | HC Wainwright & Co. | $12 → $14 | Maintains | Buy |
| 03/12/2020 | -16.2% | HC Wainwright & Co. | $13 → $12 | Reiterates | → Buy |
| 10/18/2019 | -9.22% | HC Wainwright & Co. | → $13 | Initiates Coverage On | → Buy |
| 07/11/2019 | — | Cantor Fitzgerald | Upgrades | Neutral → Overweight | |
| 11/06/2018 | 74.58% | RBC Capital | $26 → $25 | Maintains | Outperform |
What is the target price for Dynavax Technologies (DVAX)?
The latest price target for Dynavax Technologies (NASDAQ: DVAX) was reported by JMP Securities on November 3, 2023. The analyst firm set a price target for $27.00 expecting DVAX to rise to within 12 months (a possible 88.55% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Dynavax Technologies (DVAX)?
The latest analyst rating for Dynavax Technologies (NASDAQ: DVAX) was provided by JMP Securities, and Dynavax Technologies maintained their market outperform rating.
When is the next analyst rating going to be posted or updated for Dynavax Technologies (DVAX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dynavax Technologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dynavax Technologies was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
Is the Analyst Rating Dynavax Technologies (DVAX) correct?
While ratings are subjective and will change, the latest Dynavax Technologies (DVAX) rating was a maintained with a price target of $25.00 to $27.00. The current price Dynavax Technologies (DVAX) is trading at is $14.32, which is out of the analyst's predicted range.